PERSON DIRECTORY
Luba Greenwood
Luba Greenwood appears in 5 indexed conversations across Biotech Hangout. This directory brings every appearance, source, TL;DR, digest, and transcript into one searchable feed.
Episode 128 - January 24, 2025
Chris GarabedianTim OplerSam FazeliBrian SkorneyLuba Greenwood
Novo Nordisk’s Amycretin delivered 22% weight loss at 36 weeks among patients reaching 20 mg and remaining on treatment, but undisclosed discontinuations and limited tolerability data make the as-treated result provisional, making those disclosures the key valuation catalyst.Meanwhile, a roughly 5% technical XBI rebound contrasted with Stifel’s “historic high” M&A pipeline and 17 deals above $75 million upfront in 2024, while health-agency freezes threaten timelines.